Why the study?
The anti-ischaemic benefits of potent pre-hospital antiplatelet agents for STEMI need to be balanced against their increased bleeding risk.
This review summarizes current and future pre-hospital antiplatelet therapies for STEMI patients undergoing primary PCI, emphasizing the need to balance anti-ischemic benefits with bleeding risks.
Answers are grounded in this paper and cite their sources.
Supports cautious pre-hospital antiplatelet use in STEMI PCI; leaves open optimal regimens for dedicated trials.
inhibitors. Moreover, potential future management of STEMI could directly involve patients in the process of care with self-administered antiplatelet agents designed to achieve rapid reperfusion. However, the potential anti-ischaemic benefits of potent antiplatelet agents will need to be balanced against their risk of increased bleeding. This study presents a comprehensive and updated review of pre-hospital antiplatelet therapy among STEMI patients undergoing primary percutaneous intervention and explores new therapies under development.
No takes yet. Share an insight, caveat, or question.
Fabris et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: